期刊
GASTROENTEROLOGY REPORT
卷 11, 期 -, 页码 -出版社
OXFORD UNIV PRESS
DOI: 10.1093/gastro/goac083
关键词
KRAS; G12C; drug resistance; colorectal neoplasms; combination therapy
In this review, we summarized current approaches for combination therapy to alleviate resistance to KRAS G12C inhibitors in colorectal cancer, with a focus on the mechanisms of therapeutic resistance.
With the advent of Kirsten rat sarcoma viral oncogene homologue G12C (KRAS G12C) inhibitors, RAS is no longer considered undruggable. For the suppression of RAS, new therapeutic approaches have been suggested. However, current clinical studies have indicated therapeutic resistance after short-lived tumour suppression. According to preclinical studies, this might be associated with acquired genetic alterations, reactivation of downstream pathways, and stimulation for upstream signalling. In this review, we aimed to summarize current approaches for combination therapy to alleviate resistance to KRAS G12C inhibitors in colorectal cancer with a focus on the mechanisms of therapeutic resistance. We also analysed the relationship between various mechanisms and therapeutic resistance.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据